MYSM1 co-activates ERα action via histone and non-histone deubiquitination to confer antiestrogen resistance in breast cancer

Endocrine resistance is a crucial challenge in estrogen receptor alpha (ERα)-positive breast cancer (BCa) therapy. Aberrant alteration in modulation of E2/ERα signaling pathway has emerged as the putative contributor for endocrine resistance in BCa. Thus, identification the efficient ERα cofactor remains necessary for finding a potential therapeutic target for endocrine resistance. Herein, we have demonstrated that Myb like, SWIRM and MPN domains 1 (MYSM1) as a histone deubiquitinase is a novel ERα co-activator with established Drosophila experimental model. Our results showed that MYSM1 participated in up-regulation of ERα action via histone and non-histone deubiquitination. We provided the evidence to show that MYSM1 was involved in maintenance of ERα stability via ERα deubiquitination. Furthermore, silencing MYSM1 induced enhancement of histone H2A ubiquitination as well as reduction of histone H3K4me3 and H3Ac levels at cis regulatory elements on promoter of ERα-regulated gene. In addition, MYSM1 depletion attenuated cell proliferation/growth in BCa-derived cell lines and xenograft models. Knockdown of MYSM1 increased the sensitivity of antiestrogen agents in BCa cells. MYSM1 was highly expressed in clinical BCa samples, especially in aromatase inhibitor (AI) non-responsive tissues. These findings clarify the molecular mechanism of MYSM1 as an epigenetic modifier in regulation of ERα action and provide a potential therapeutic target for endocrine resistance in BCa.

[1]  X. Meng,et al.  MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway , 2022, Cell death discovery.

[2]  Fan Yang,et al.  MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling , 2021, Journal of experimental & clinical cancer research : CR.

[3]  V. Malladi,et al.  PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α–Positive Breast Cancer Cells , 2021, Molecular Cancer Research.

[4]  J. Pelletier,et al.  Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma , 2021, Journal of cellular and molecular medicine.

[5]  Jieyi Wang,et al.  USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α , 2021, Cell Death & Disease.

[6]  A. Kottorou,et al.  Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer. , 2021, Cancer letters.

[7]  C. Allis,et al.  The language of chromatin modification in human cancers , 2021, Nature Reviews Cancer.

[8]  Jinbao Liu,et al.  The deubiquitinating enzyme USP15 stabilizes ERα and promotes breast cancer progression , 2021, Cell Death & Disease.

[9]  Ho Lam Chan,et al.  Epigenetic mechanisms in breast cancer therapy and resistance , 2021, Nature Communications.

[10]  M. Hendzel,et al.  Polycomb group-mediated histone H2A monoubiquitination in epigenome regulation and nuclear processes , 2020, Nature Communications.

[11]  Jianguo Wu,et al.  MYSM1 Suppresses Cellular Senescence and the Aging Process to Prolong Lifespan , 2020, Advanced science.

[12]  F. Jin,et al.  An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer , 2020, Nucleic acids research.

[13]  P. Gros,et al.  MYSM1 maintains ribosomal protein gene expression in hematopoietic stem cells to prevent hematopoietic dysfunction. , 2020, JCI insight.

[14]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[15]  D. Pasini,et al.  Histone H2AK119 Mono-Ubiquitination Is Essential for Polycomb-Mediated Transcriptional Repression , 2019, bioRxiv.

[16]  K. Korach,et al.  Estrogen Receptors: New Directions in the New Millennium. , 2018, Endocrine reviews.

[17]  M. Muyan,et al.  Molecular mechanism of estrogen–estrogen receptor signaling , 2016, Reproductive medicine and biology.

[18]  N. Gekara,et al.  Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes. , 2015, Immunity.

[19]  Liu Cao,et al.  MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer , 2015, Nucleic acids research.

[20]  N. Donato,et al.  Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. , 2014, Cancer research.

[21]  S. Jackson,et al.  Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity , 2014, Nature Cell Biology.

[22]  K. Knudsen,et al.  Transcriptional Roles of PARP1 in Cancer , 2014, Molecular Cancer Research.

[23]  Tao Wang,et al.  The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. , 2013, Blood.

[24]  Kosuke Yusa,et al.  The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiation. , 2012, Blood.

[25]  Yu Shyr,et al.  A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance , 2011, Clinical Cancer Research.

[26]  Rong Li,et al.  Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions , 2008, Oncogene.

[27]  C. Glass,et al.  A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. , 2007, Molecular cell.

[28]  M. Yaffe.  Faculty Opinions recommendation of A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. , 2006 .

[29]  K. Bomsztyk,et al.  Protocol for the fast chromatin immunoprecipitation (ChIP) method , 2006, Nature Protocols.

[30]  W. Shao,et al.  Coactivator AIB1 links estrogen receptor transcriptional activity and stability. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Jiang,et al.  Estrogen receptor corepressors -- a role in human breast cancer? , 2003, Endocrine-related cancer.